Clinical trials: Advanced Cancers
Solid Tumor
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC729 in the treatment of advanced malignant solid tumors. Condition or disease:advanced malignant solid tumors.
- Trial name
- NCT06394622
- Testing
- Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Fudan University
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
- Trial name
- NCT05783622
- Testing
- JANX008
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Janux Therapeutics
Breast Cancer Metastatic
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.
- Trial name
- NCT01876251
- Testing
- PF-03084014, Docetaxel
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 30 people
- Sponsor
- Pfizer
Head and Neck Cancer
Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiosensitizing drugs, such as cytochlor and tetrahydrouridine, may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00077051
- Testing
- cisplatin, cytochlor, tetrahydrouridine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Rectal Neoplasms
Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer
Neoadjuvant chemoradiation (CRT), is considered the standard treatment of locally advanced rectal cancer with a positive impact on locoregional control and survival.However, patients with T4 rectal cancer show high risk of local…
- Trial name
- NCT02723253
- Testing
- Radiotherapy, Tom-OX
- Volunteers
- 18 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Locally Advanced or Metastatic Breast Cancer
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
Study E7389-M044-504 is an observational, post-authorization, single-arm, prospective, multicenter cohort study conducted to characterize and determine the incidence of eribulin-induced peripheral neuropathy (PN), and the…
- Trial name
- IRENE (NCT03027245)
- Testing
- Eribulin
- Where
- 65 sites in Germany
- Volunteers
- 353 people
- Sponsor
- Eisai GmbH
Locally Advanced Rectal Cancer
Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
Phase II clinical trial, open-label, randomized, two arms, multicentre (possibly multinational). Academic, investigator initiated.
- Trial name
- AXEBEAM (NCT00828672)
- Testing
- Oxaliplatin, Bevacizumab, Capecitabine
- Where
- 9 sites in Belgium
- Volunteers
- 84 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Biliary Tract Cancer
Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer
Biliary tract cancer is relatively rare cancer, with generally poor prognosis. In metastatic/recurrent biliary tract cancer, the most commonly used 1st-line chemotherapy is gemcitabine+cisplatin combination.
- Trial name
- NCT02433639
- Testing
- TH-302 monotherapy
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Seoul National University Hospital
Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II
Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) with concurrent chemotherapy in the management of stage II and III non-small cell lung cancer (NSCLC).
- Conditions
- Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- NCT05873439
- Testing
- Genomically Guided Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Breast Cancer
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
The purpose of this study is to determine the safety profile, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), of oral vorinostat in combination with oral capecitabine given on days 1-7 and 15-21 of a 28 day cycle in…
- Trial name
- NCT00719875
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Yale University
Pancreatic Cancer, Chemotherapy Effect
Modified-FOLFIRINOX Regimen Based Neoadjuvant Therapy in Chinese Patients With Locally Advanced Pancreatic Cancer
FOLFIRINOX regimen is first-line neoadjuvant chemotherapies for patients with locally advanced pancreatic cancer (LAPC) worldwide.
- Conditions
- Pancreatic Cancer, Chemotherapy Effect, Surgery--Complications
- Trial name
- NCT03469375
- Testing
- modified-FOLFIRINOX
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
This phase II MATCH treatment trial tests how well crizotinib works in treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06357975
- Testing
- Biopsy Procedure, Biospecimen Collection, Crizotinib
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Lung Neoplasms, Psychological Distress
Association of Psychological Distress in Patients With Lung Cancer
Psychological distress is a multi-factorial experience of a psychological, social, spiritual, and/or physical nature that may interfere with one's ability to cope effectively with cancer, physical symptoms and treatment.
- Conditions
- Lung Neoplasms, Psychological Distress, Prognosis Factors, Lifestyle, Healthy
- Trial name
- Life-Score (NCT06218901)
- Testing
- immunotherapy, Targeted Therapy Agent
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Hepatocellular Carcinoma
A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients
This trial is a single-arm, open, multicenter phase II clinical study.Subjects can only enter this study after they meet the inclusion and exclusion criteria.Into subjects will accept HLX10 + HLX04 intravenous infusion, every two…
- Trial name
- NCT03973112
- Testing
- HLX10 3mg/kg, HLX04 5mg/kg, HLX04 10mg/kg
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Non-Small Cell Lung Cancer
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy.
- Trial name
- NCT03516981
- Testing
- Pembrolizumab, Favezelimab, Lenvatinib
- Where
- 81 sites in United States, Australia and 14 more
- Volunteers
- 245 people
- Sponsor
- Merck Sharp & Dohme LLC
Urothelial Carcinoma
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
The purpose of this study is to explore the safety and activity of docetaxel + ASA404 as second-line chemotherapy in patients with advanced urothelial carcinoma.
- Trial name
- NCT01071928
- Testing
- Docetaxel, ASA404
- Sponsor
- Hoosier Cancer Research Network
Malignant Solid Tumor
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.
- Trial name
- NCT02754141
- Testing
- BMS-986179, Nivolumab, rHuPH20
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 235 people
- Sponsor
- Bristol-Myers Squibb
Squamous Non Small Cell Lung Cancer
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10 + chemotherapy vs chemotherapy in subjects with locally advanced or metastatic squamous NSCLC…
- Trial name
- NCT04033354
- Testing
- HLX10, carboplatin and nab paclitaxel
- Where
- 92 sites in United States, China and 5 more
- Volunteers
- 537 people
- Sponsor
- Shanghai Henlius Biotech
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT04675294
- Testing
- evorpacept, pembrolizumab
- Where
- 53 sites in United States, Australia and 7 more
- Volunteers
- 189 people
- Sponsor
- ALX Oncology Inc.
Solid Tumor
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 dose-escalation and expansion study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of SAIL66 in patients with CLDN6-positive locally advanced…
- Trial name
- NCT05735366
- Testing
- SAIL66
- Where
- 9 sites in United States, Japan
- Volunteers
- 22 people
- Sponsor
- Chugai Pharmaceutical